
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Teva Pharma Industries Ltd ADR (TEVA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: TEVA (2-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $23.56
1 Year Target Price $23.56
6 | Strong Buy |
4 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 24.42% | Avg. Invested days 58 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 20.76B USD | Price to earnings Ratio - | 1Y Target Price 23.56 |
Price to earnings Ratio - | 1Y Target Price 23.56 | ||
Volume (30-day avg) 11 | Beta 0.62 | 52 Weeks Range 12.47 - 22.80 | Updated Date 08/28/2025 |
52 Weeks Range 12.47 - 22.80 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.15 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-30 | When - | Estimate 0.63 | Actual 0.66 |
Profitability
Profit Margin -0.94% | Operating Margin (TTM) 21.41% |
Management Effectiveness
Return on Assets (TTM) 5.37% | Return on Equity (TTM) -2.42% |
Valuation
Trailing PE - | Forward PE 6.95 | Enterprise Value 36044131084 | Price to Sales(TTM) 1.25 |
Enterprise Value 36044131084 | Price to Sales(TTM) 1.25 | ||
Enterprise Value to Revenue 2.17 | Enterprise Value to EBITDA 19.02 | Shares Outstanding 1147149952 | Shares Floating 1141529878 |
Shares Outstanding 1147149952 | Shares Floating 1141529878 | ||
Percent Insiders - | Percent Institutions 66.14 |
Upturn AI SWOT
Teva Pharma Industries Ltd ADR

Company Overview
History and Background
Teva Pharmaceutical Industries Ltd. was founded in 1901 in Jerusalem. Initially a small wholesaler, it evolved into a global pharmaceutical company through organic growth and strategic acquisitions, focusing on generic and specialty medicines.
Core Business Areas
- Generic Medicines: Teva is a leading generic pharmaceutical manufacturer, producing a wide range of generic drugs across various therapeutic areas.
- Specialty Medicines: Teva develops and markets specialty medicines, focusing on central nervous system (CNS) disorders, pain, and respiratory diseases.
- Biopharmaceuticals: Teva has a growing biopharmaceutical business, developing biosimilars and innovative biologics.
Leadership and Structure
Teva is led by a CEO and a board of directors. The organizational structure includes global functions such as R&D, operations, and commercial operations, along with regional business units.
Top Products and Market Share
Key Offerings
- Copaxone: A specialty medicine for multiple sclerosis (MS). While patent protection has expired, it remains a significant revenue contributor. Competitors include Biogen (Tecfidera), Novartis (Gilenya), and Roche (Ocrevus).
- Generic Medicines Portfolio: Teva has a broad portfolio of generic drugs, including generics for high-demand medications across multiple therapeutic areas. Competitors include Mylan (Viatris), Sandoz (Novartis), and Sun Pharmaceutical.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. The generic drug market is driven by patent expirations and cost-containment pressures, while the specialty drug market is focused on innovative therapies for unmet medical needs.
Positioning
Teva is a leading generic pharmaceutical company with a strong presence in specialty medicines. Its competitive advantage lies in its broad product portfolio, global manufacturing network, and expertise in generic drug development.
Total Addressable Market (TAM)
The global pharmaceuticals market is estimated at over $1 trillion. Teva targets both the generic and specialty segments. Its TAM is significant, with positioning focused on affordability and access through generics, and innovation in specialty areas.
Upturn SWOT Analysis
Strengths
- Global Manufacturing and Distribution Network
- Extensive Portfolio of Generic Drugs
- Established Presence in Specialty Medicines
- Strong R&D Capabilities in Generics
Weaknesses
- High Debt Levels
- Loss of Exclusivity on Key Products (e.g., Copaxone)
- Exposure to Pricing Pressure in the Generic Market
- Litigation and Regulatory Risks
Opportunities
- Growth in Emerging Markets
- Development of Biosimilars
- Strategic Partnerships and Acquisitions
- Expansion of Specialty Medicines Portfolio
Threats
- Increased Competition from Generic Manufacturers
- Patent Challenges and Litigation
- Pricing Regulations and Reimbursement Pressures
- Economic Downturns Impacting Healthcare Spending
Competitors and Market Share
Key Competitors
- VTRS
- NVS
- SUN
Competitive Landscape
Teva faces stiff competition in both the generic and specialty pharmaceutical markets. It is focusing on cost efficiencies and strategic partnerships to maintain its competitive position. Teva has an advantage in generics due to its wide portfolio, but it faces pricing pressure. Teva's focus on debt reduction will allow it to invest more in innovation and strategic growth.
Major Acquisitions
Actavis Generics
- Year: 2016
- Acquisition Price (USD millions): 40500
- Strategic Rationale: Acquired Actavis Generics to expand its generic drug portfolio and global reach, however, the size of this acquisition has contributed to Teva's high debt
Growth Trajectory and Initiatives
Historical Growth: Teva's growth has been challenged in recent years due to generic pricing pressure and loss of exclusivity on key products.
Future Projections: Analyst estimates vary, but projections generally anticipate modest revenue growth driven by new product launches and expansion in emerging markets. Profitability improvements are expected as debt is reduced.
Recent Initiatives: Teva is focused on debt reduction, streamlining operations, and investing in its pipeline of specialty and biosimilar products.
Summary
Teva faces challenges stemming from its high debt load and generic pricing pressures. However, it maintains a strong position in the generic market with a vast portfolio and global distribution network. Strategic focus on debt reduction and specialty medicines may provide a path to sustained growth. Investors should watch for improvements in profitability and pipeline development as key indicators.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (10K, 10Q), Analyst reports, Market research reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Teva Pharma Industries Ltd ADR
Exchange NYSE | Headquaters - | ||
IPO Launch date 1990-03-26 | President, CEO & Director Mr. Richard D. Francis | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 37000 | Website https://www.tevapharm.com |
Full time employees 37000 | Website https://www.tevapharm.com |
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders " chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.